AZD-0284

Cat. No.:	HY-120384	
CAS No.:	2101291-07-8	
Molecular Formula:	C ₂₁ H ₁₈ F ₆ N ₂ O ₅ S	
Molecular Weight:	524	
Target:	ROR	
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor	
Storage:	4°C, stored under nitrogen	
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)	

Product Data Sheet

HO

-F

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (190.84 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.9084 mL	9.5420 mL	19.0840 mL		
		5 mM	0.3817 mL	1.9084 mL	3.8168 mL		
		10 mM	0.1908 mL	0.9542 mL	1.9084 mL		
	Please refer to the sol	ubility information to select the app	propriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (1.58 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.83 mg/mL (1.58 mM); Clear solution						
	3. Add each solvent o Solubility: ≥ 0.83 m	one by one: 10% DMSO >> 90% cor ng/mL (1.58 mM); Clear solution	n oil				

Description	AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment ^[1] .			
IC ₅₀ & Target	pIC50: 7.4 (FRET RORγ) ^[1]			
In Vitro	AZD0284 (0.37 μM; 5 days) inhibits IL-17A production in human T _H 17 cells ^[1] . AZD0284 reduces polarization of T _H 17 into pathogenic T _H 17/1 cells. AZD0284 decreases frequency of single IL-17 ⁺ cell as well as double positive T _H 17/1 cells. AZD0284 reduces IL-17A secretion and RNA expression of IL-17A, IL-17F, IL-22 and IL-23R ^{[1][2]}			

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Narjes, F, et al. The discovery of AZD0284, an inverse agonist of the nuclear receptor RORg. American Chemical Society, 2017 Drug Design and Delivery Symposium 26 October 2017

[2]. Asimus S, et al. Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284 [published online ahead of print, 2020 Feb 17]. Br J Clin Pharmacol. 2020;10.1111/bcp.14253.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA